Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Baker Tilly Wealth Management LLC

Baker Tilly Wealth Management LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 58.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,300 shares of the biopharmaceutical company's stock after selling 3,273 shares during the quarter. Baker Tilly Wealth Management LLC's holdings in Gilead Sciences were worth $258,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bridgewater Associates LP grew its stake in Gilead Sciences by 122.7% during the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock valued at $42,577,000 after purchasing an additional 253,994 shares during the last quarter. Nissay Asset Management Corp Japan ADV boosted its position in Gilead Sciences by 5.2% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after buying an additional 14,009 shares during the last quarter. Jennison Associates LLC acquired a new position in Gilead Sciences in the 4th quarter worth approximately $87,163,000. Columbus Macro LLC raised its position in Gilead Sciences by 55.9% during the 4th quarter. Columbus Macro LLC now owns 25,103 shares of the biopharmaceutical company's stock worth $2,319,000 after buying an additional 9,004 shares during the last quarter. Finally, NatWest Group plc purchased a new position in Gilead Sciences during the 4th quarter worth approximately $6,808,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the transaction, the chief financial officer now owns 169,061 shares of the company's stock, valued at $19,977,938.37. This represents a 9.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the sale, the insider now owns 121,152 shares of the company's stock, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 60,929 shares of company stock valued at $6,748,980 in the last quarter. Insiders own 0.27% of the company's stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of research reports. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price for the company in a research report on Thursday, February 13th. Royal Bank of Canada upped their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Cantor Fitzgerald started coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective on the stock. Finally, Morgan Stanley raised their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Trading Down 0.3%

Gilead Sciences stock traded down $0.31 during midday trading on Wednesday, hitting $109.02. 7,963,204 shares of the stock were exchanged, compared to its average volume of 7,730,101. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock's 50-day simple moving average is $105.45 and its 200 day simple moving average is $101.10. Gilead Sciences, Inc. has a fifty-two week low of $62.69 and a fifty-two week high of $119.96. The stock has a market capitalization of $135.61 billion, a price-to-earnings ratio of 294.65, a PEG ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business's revenue was down .3% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.32) EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.90%. Gilead Sciences's dividend payout ratio is currently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.